Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05936580 · ClinicalTrials.gov registry record · Phase 4
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
A Phase 4 study of Hemophilia A, sponsored by Octapharma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 15
- Study locations
NCT05936580 is a Phase 4 study of Hemophilia A that is actively recruiting participants, run by Octapharma. The registered enrollment target is 28 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (69% lower). The trial reports 15 study locations across 2 states.
The verdict
NCT05936580, a Phase 4 study of Hemophilia A, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 15
- Study locations
Study Summary
Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery
Conditions Studied
Interventions
- DRUG Nuwiq
Study Locations (15)
Other
- Helsinki University Hospital,Coagulation Disorder Unit - Helsinki
- Avenue de la République - Chambray-lès-Tours
- CHU de Nantes Hôtel-Dieu - Nantes
- Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin - Bonn
- Gerinnungszentrum Rhein-Ruhr - Duisburg
- Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik - Hamburg
- Aziendo Ospedaliera "Puglieze Ciaccio" - Catanzaro
- Policlinico "P. Giaconne" - Palermo
- Clinical Center for Serbia - Belgrade
- Hospital Universitario la Paz - Madrid
- Hospital Universitario Virgen del Rocio - Seville
- Insel Spital Bern - Bern
- St. James's University Hospital - Leeds
- Centro Hospitalario Pereira Rossell - Montevideo
Texas
- UT Health San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05936580
The ClinicalTrials.gov registry entry for NCT05936580 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (69% lower). The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Nuwiq is the first listed.
NCT05936580 reports 15 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.
Frequently Asked Questions
What is clinical trial NCT05936580 about?
NCT05936580 is a clinical study titled "Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery". Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery
What is the current status of trial NCT05936580?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2026-04. Estimated completion is 2027-02.
What conditions does trial NCT05936580 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT05936580?
The interventions under investigation include: Nuwiq (DRUG).
Who is sponsoring clinical trial NCT05936580?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05936580 being conducted?
This trial has 15 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
RECRUITING · Phase 4
-
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
RECRUITING · Phase 4
-
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
COMPLETED · Phase 4
-
Prophylaxis Regimen for Hemophilia A Patients
COMPLETED · Phase 4
-
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
COMPLETED · Phase 4
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.